InflaRx N.V.
IFRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. Valued at $353.5M, IFRX is a small-cap name in its sector. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Market Cap
$353.5M
Beta
2.44
P/E (TTM)
—
P/E (Fwd)
-5.52
EPS (TTM)
$-0.73
EPS (Fwd)
$-0.44
ROE
-79.9%
ROA
-39.1%
Cash
$39.8M
Total Debt
$823,028
Free CF
-$15.9M
52W Change
196.3%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $39.8M in cash comfortably exceeding the $823K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$15.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -79.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, IFRX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, IFRX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing IFRX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.